Akili Interactive Labs, Inc.   Report issue

For profit
Founded: Boston MA United States (2011)

Organization Overview

First Clinical Trial
2016
NCT02822937
First Marketed Drug
None
First NDA Approval
None
Last Known Activity
2021

Timeline

NOW
  • Now

Alternative names

Akili Interactive Labs, Inc.

Active Ingredients

Drugs in Other Trials (2)

methylphenidate (ritalin) (1 trial)

triazolam (halcion) (1 trial)

Indications

Overview

  • Highest Phase: Phase 0
  • # of Trials: 1
  • # of Trial APIs: 2